Alterity Therapeutics (ATHE) Net Income towards Common Stockholders (2016 - 2020)

Alterity Therapeutics' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at $6.3 million for Q4 2020.

• In Q4 2020, Net Income towards Common Stockholders rose 262.41% year-over-year to $6.3 million; the TTM figure through Jun 2022 stood at $6.3 million (up 2.57% YoY), while the FY2025 annual figure was -$7.8 million, up 38.27% from the prior year.
• Net Income towards Common Stockholders was $6.3 million for Q4 2020 at Alterity Therapeutics, up from $3.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $6.3 million in Q4 2020 to a low of -$3.9 million in Q4 2019.
• Historically, Net Income towards Common Stockholders has averaged -$541821.7 across 5 years, with a median of -$2.8 million in 2016.
• The sharpest annual moves came in 2018 and 2020: Net Income towards Common Stockholders tumbled 37.71% in 2018, then soared 262.41% in 2020.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.7 million in 2016, then dropped by 1.55% to -$2.8 million in 2017, then plunged by 37.71% to -$3.8 million in 2018, then dropped by 0.58% to -$3.9 million in 2019, then jumped by 262.41% to $6.3 million in 2020.
• The last three Net Income towards Common Stockholders figures came in at $6.3 million (Q4 2020), $3.7 million (Q2 2020), and -$3.9 million (Q4 2019), per Business Quant data.